Home › Breast Cancer › Illinois
Breast Cancer clinical trials in Illinois
81 studies for Breast Cancer are looking for participants at sites in Illinois.
Cities in Illinois
- Chicago58 studies
- Waukegan13 studies
- Evanston13 studies
- Champaign11 studies
- Cicero11 studies
- Naperville9 studies
- Peoria8 studies
- Decatur8 studies
- Springfield8 studies
- Arlington Heights7 studies
- Aurora7 studies
- Carbondale6 studies
- Charleston5 studies
- Rockford5 studies
- North Peoria5 studies
- Bloomington5 studies
- Danville5 studies
- Galesburg5 studies
- Joliet4 studies
- Elgin4 studies
Study to Understand Relationship Between Gut Health and Toxicities of Hormonal Breast Cancer Treatment
- The University of Chicago Medicine Comprehensive Cancer Center, Chicago
Recruiting
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07553234A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, Chicago
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06103864A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- University of Illinois Cancer Center, Chicago
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06172478A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Rush University Medical Center ( Site 0079), Chicago
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06312176ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- City of Hope Chicago, Zion
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07007559Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- Northwestern University, Chicago
Recruiting
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07214532Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Affiliated Oncologists IL, Chicago
- Hope And Healing Care, Hinsdale
- Midwestern Reg MC COH Chicago, Zion
RecruitingPhase 3
Ages 18 to 100 · All sexes · Updated Sep 23, 2026 · NCT05827081Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Clinical Trial Site, Peoria
- Clinical Trial Site, Urbana
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07085767A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- City of Hope, Chicago, Chicago
- Northwestern Memorial Hospital, Chicago
- University of Illinois at Chicago, Chicago
- and 3 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07174336Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
- University of Chicago, Chicago
RecruitingHealthy volunteers welcome
Ages 30 to 74 · Women · Updated Sep 21, 2026 · NCT02620852A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
- University of Illinois Hospital & Health Sciences System, Chicago
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT06827236ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- Cancer Care Specialists, Decatur
- Cancer Care Specialists of Illinois, O'Fallon
- Carle Foundation Hospital d/b/a Carle Cancer Center, Urbana
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07173751A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- City of Hope, Chicago, Zion
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07109726Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Orchard Healthcare Research Inc.- Skokie, Skokie
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT06324357A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Illinois Cancer Specialists, Arlington Heights
- Northwestern Memorial Hospital, Chicago
- RUSH MD Anderson Cancer Center, Chicago
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT06492616SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation
- Orchard Healthcare Research Inc., Skokie
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT05935384Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
- Orchard Healthcare Research Inc. ( Site 0006), Skokie
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT06797635Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- University of Illinois Cancer Center, Chicago
- University of Chicago Medicine, Chicago
- City of Hope - Chicago, Zion
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT06293898A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- City of Hope® Cancer Center Chicago, Zion
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT03424005A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
- NorthShore University Health System - Evanston Hospital, Evanston
- NorthShore University HealthSystem - Evanston Hospital, Evanston
- Duly Health and Care, Lisle
- and 2 more
RecruitingPhase 1
Ages 18 to 55 · Women · Updated Sep 9, 2026 · NCT07310420Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- Carle Cancer Center, Urbana
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT05386108A Phase 1/1b Study of IAM1363 in HER2 Cancers
- University of Chicago, Chicago
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT06253871A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
- Research Site, Evanston
RecruitingPhase 3
Ages 18 to 130 · All sexes · Updated Sep 8, 2026 · NCT07647328A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
- City of Hope® Cancer Center Chicago, Zion
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT07100106Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
- Northwestern University, Chicago
- Rush University Medical Center, Chicago
- University of Chicago, Chicago
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 4, 2026 · NCT06062498Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
- Northwestern University, Chicago
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 4, 2026 · NCT05315700Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- Southern Illinois Hospital Services, Carbondale
- Cancer Care Specialist of Illinois, O'Fallon
RecruitingObservational study
Ages 18 to 99 · All sexes · Updated Sep 3, 2026 · NCT07211178A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Cancer Care Specialists of Central Illinois, O'Fallon
- Springfield Clinic, Springfield
- Carle Cancer Center, Urbana
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06790693Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
- University of Illinois Cancer Center, Chicago
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT04886531Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Rush University Medical Center, Chicago
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06982521Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- OSF Saint Anthony's Health Center, Alton
- Advocate Outpatient Center - Aurora, Aurora
- Advocate Good Shepherd Hospital, Barrington
- and 83 more
RecruitingPhase 3
Ages 18 to 60 · Women · Updated Sep 2, 2026 · NCT05879926PRE-ISPY Phase I/II Oncology Platform Program
- The University of Chicago Medicine Comprehensive Cancer Center, Chicago
- UChicago Medicine Comprehensive Cancer Center at Silver Cross Hospital, New Lenox
- UChicago Medicine Orland Park, Orland Park
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT05868226Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- OSF Saint Anthony's Health Center, Alton
- Rush-Copley Medical Center, Aurora
- Advocate Outpatient Center - Aurora, Aurora
- and 54 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Sep 2, 2026 · NCT05334069Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- Northwestern University, Chicago
- Southern Illinois University-Simmons, Springfield
- Carle Foundation Cancer Institute-Urbana, Urbana
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06072612A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer
- University Of Chicago Medicine Comprehensive Cancer Center, Chicago
RecruitingHealthy volunteers welcome
Ages 25 and older · Women · Updated Sep 1, 2026 · NCT03729115TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
- University of Chicago Medical Center, Chicago
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 26, 2026 · NCT06533826BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer
- University of Illinois, Chicago
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 21, 2026 · NCT06441890A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
- Robert H. Lurie Comprehensive Cancer Center Northwestern University, Chicago
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 21, 2026 · NCT06764940ATEMPT 2.0: Adjuvant T-DM1 vs TH
- The University of Chicago Medical Center, Chicago
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT04893109Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
- Alton Memorial Hospital, Alton
- Northwestern University, Chicago
- Northwestern Medicine Cancer Center Kishwaukee, DeKalb
- and 3 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT06500481From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.